Related Experiment Videos

Acantholytic dyskeratotic acanthoma: a possible skin adverse event of vemurafenib treatment

T Komori¹, A Otsuka¹, Y Kaku¹

¹Department of Dermatology, Kyoto University Graduate School of Medicine, 606-8507, Kyoto, Japan.

Journal of the European Academy of Dermatology and Venereology : JEADV

|April 21, 2017

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Upadacitinib for moderate-to-severe atopic dermatitis: Stratified analysis from three randomized phase 3 trials by key baseline characteristics.

Journal of the European Academy of Dermatology and Venereology : JEADV·2023

Estimands for atopic dermatitis clinical trials: Expert opinion on the importance of intercurrent events.

Journal of the European Academy of Dermatology and Venereology : JEADV·2023

Atopic dermatitis: pathomechanisms and lessons learned from novel systemic therapeutic options.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022

Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study).

ESMO open·2021

Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long-term studies.

The British journal of dermatology·2021

Longitudinal association between polypharmacy and development of pruritus: a Nationwide Cohort Study in a Japanese Population.

Journal of the European Academy of Dermatology and Venereology : JEADV·2021

See all related articles